Skip to main content

Table 7 Fluorescence-activated cell sorting analysis of TBG-Dy uptake

From: Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy

Cell line or tumor

Treatment

Dy-positive (%)

MDA-MB-231

Untreated

1.9

MDA-MB-231

TBG-Dy 1×

14.4

MDA-MB-231

TBG-Dy 2×

21.5

SUM-149

Untreated

0.9

SUM-149

TBG-Dy

13.1

SUM-149 tumor 1

Untreated

1.2

SUM-149 tumor 2

i.v. TBG-Dy

36.0

SUM-149 tumor 3

i.v. TBG-Dy

37.1

SUM-149 tumor 4

i.v. TBG-Dy

28.5

MDA-MB-231 tumor 1

Untreated

1.7

MDA-MB-231 tumor 2

i.v. TBG-Dy

11.0

  1. Dy, dysprosium; i.v., intravenous; TBG, tenfibgen.